20.02.2017 • NewsDede WillamscmaPfizer

Pfizer Appeals UK Fine Over NHS Hike

(c) arturbo
(c) arturbo

US drugs giant Pfizer has challenged the record £84 million fine imposed by the UK’s Competition and Markets Authority (CMA) for a supply scheme that resulted in a 2,600% price overnight increase on an epilepsy drug sold to the country’s National Health System.

Flynn Pharma, the drug’s US-based distributor, has separately filed an appeal challenging its £5.2 million fine. The two companies said the decision should be annulled and the fines set aside or reduced.

According to CMA, the UK health authority’s spending on the phenytoin sodium capsules used by 48,000 patients in the UK rose from £2 million in 2012 to around £50 million in 2013 and were “many times” higher than Pfizer charged in other European countries.

Both Pfizer and Flynn disputed the CMA findings that they were “dominant” players in the market for the drug, claiming also that the authority “ignored market realities” in saying the prices were exorbitant. In fact, they said, said the authority did not take into account that the price charged by the distributor was less than what the NHS paid for a comparable version of the drug from another supplier.

In the meantime Pfizern said it has reduced the price at which it supplies phenytoin sodium capsules to Flynn Pharma to the price suggested by CMA.  In the past, the US drugmaker defended its arrangement with Flynn as a chance to secure ongoing supply of an important medicine that it had been having to sell at a loss.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.